LEADER 01649nam0 22003611i 450 001 UON00506470 005 20231205105438.67 010 $a978-04-7207-410-5 100 $a20211103d2019 |0itac50 ba 101 $aeng 102 $aUS 105 $a|||| ||||| 200 1 $aˆThe ‰burden of the past$eproblems of historical perception in Japan-Korea relations$fKan Kimura$gTranslated by Marie Speed$gforeword by Gi-Wook Shin 210 $aAnn Arbor$cUniversity of Michigan Press$d2019 215 $axiv, 249 p.$cill.$d24 cm 311 $aCOR IV A 155 N$9UON00506476 312 $aIn inglese$9UON00506475 410 0$1001UON00506476$12001 $aJapan library$fJPIC, Japan Publishing Industry Foundation for Culture$v COR IV A 155 N 500 0$3UON00506475$aNikkan rekishi ninshiki mondai to wa nani ka$91885698 606 $aRELAZIONI INTERNAZIONALI$xCOREA/GIAPPONE$3UONC004027$2FI 606 $aGIAPPONE$xRELAZIONI ESTERE$x1945-$3UONC055863$2FI 620 $aUS$dAnn Arbor (Michigan)$3UONL000025 686 $aCOR IV A$cCOREA - STORIA MODERNA E CONTEMPORANEA$2A 700 0$aKimura Kan$3UONV285875$0845231 702 0$aSHIN Gi-Wook$3UONV229831$4075 702 1$aSpeed$bMarie$3UONV285876$4730 712 $aUniversity of Michigan$3UONV245968$4650 801 $aIT$bSOL$c20240220$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00506470 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI COR IV A 155 N $eSI 37805 5 155 N 996 $aNikkan rekishi ninshiki mondai to wa nani ka$91885698 997 $aUNIOR LEADER 02919nam 2200877z- 450 001 9910566459103321 005 20220506 035 $a(CKB)5680000000037790 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81067 035 $a(oapen)doab81067 035 $a(EXLCZ)995680000000037790 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPharmacogenomics$eFrom Basic Research to Clinical Implementation 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (162 p.) 311 08$a3-0365-2835-0 311 08$a3-0365-2834-2 330 $aThis Special Issue focuses on the current state of pharmacogenomics (PGx) and the extensive translational process, including the identification of functionally important PGx variation; the characterization of PGx haplotypes and metabolizer statuses, their clinical interpretation, clinical decision support, and the incorporation of PGx into clinical care. 517 $aPharmacogenomics 606 $aMedicine and Nursing$2bicssc 606 $aPharmacology$2bicssc 610 $aadaptation 610 $aartificial intelligence 610 $abest practice alerts (BPAs) 610 $achronic disease 610 $achronic kidney disease 610 $aclinical actionability 610 $aclinical decision support (CDS) 610 $aclinical translation 610 $acommunity pharmacy 610 $aCYP3A5 610 $aelectronic health records (EHR) 610 $aelectronic medical record 610 $agenetic counseling 610 $agenetic privacy 610 $agenomic indicators 610 $agenotype 610 $ahuman evolution 610 $aimplementation 610 $amachine learning 610 $amedication management 610 $an/a 610 $apediatrics 610 $apersonalized medicine 610 $apharmaco-economics 610 $apharmacogenes 610 $apharmacogenetics 610 $apharmacogenetics service 610 $apharmacogenomic 610 $apharmacogenomic testing 610 $apharmacogenomics 610 $apharmacogenomics (PGx) 610 $aphenotype 610 $apolymorphism 610 $apolymorphisms 610 $apolypharmacy 610 $apre-emptive 610 $aprecision medicine 610 $aprogression 610 $aqualitative 610 $areturn of results 610 $ascreening 610 $aUS Food and Drug Administration 615 7$aMedicine and Nursing 615 7$aPharmacology 700 $aScheinfeldt$b Laura B$4edt$01299056 702 $aScheinfeldt$b Laura B$4oth 906 $aBOOK 912 $a9910566459103321 996 $aPharmacogenomics$93025009 997 $aUNINA